Ligand Pharmaceuticals Incorporated
LGNDHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeLigand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. The $5.76B market capitalization puts LGND squarely in mid-cap range for its industry. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.
Market Cap
$5.76B
Beta
0.98
P/E (TTM)
29.75
P/E (Fwd)
24.20
EPS (TTM)
$9.71
EPS (Fwd)
$11.93
ROE
22.0%
ROA
4.0%
Cash
$1.36B
Total Debt
$1.13B
Free CF
$139.7M
52W Change
72.1%
Annual Financials
Cash vs Debt
Where LGND stands vs its 150-day and 200-day moving averages
As of the July 30, 2026 close, LGND finished 26.47% above its 150-day moving average ($227.73) and 31.45% above its 200-day moving average ($219.11). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LGND overbought or oversold?
At the July 30, 2026 close, LGND's RSI(14) was 25.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $1.36B in cash and $1.13B in debt, LGND maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $139.7M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 22.0% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.0% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $196.2M (2022) to $268.1M (2025), reflecting a 37% increase over the period.
As with any equity investment, LGND carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Ligand Pharmaceuticals Incorporated's trajectory.